Dyno Therapeutics Emerges With Novartis, Sarepta Deals For Novel AAV Capsids
Executive Summary
Dyno raised $9m in 2018 but came out of stealth mode with deals worth up to $2bn based on its platform using high throughput biology, AI and machine learning to engineer next-generation AAV capsids.
You may also be interested in...
Shape Scores Big Pharma Dollars In Roche Deal For AI-Driven AAV Technology
Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy.
Shape Therapeutics’ Big Financing Shows Growing Interest In Novel Capsids
Several companies have recently raised large amounts of money from venture capital as well as potentially through partnerships for next-generation capsid technology.
Biogen/Capsigen Ink Up To $1.3bn Deal For Improved AAV Capsids
Biogen is Capsigen’s first partner, while Dyno Therapeutics has also entered into deals potentially worth billions with large drug and biotech firms.